TBRIF
Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.01 | $19,346 | -$136,303 |
| 2025 Q1 | -0.00 | $0 | -$38,763 |
| 2025 Q4 | -0.04 | $33,431 | -$38,148 |
| 2025 Q3 | -0.00 | $1,813 | $48,474 |
| 2025 Q2 | -0.00 | $27,096 | -$140,257 |
| 2024 Q1 | -0.00 | $5,041 | -$16,598 |
| 2024 Q4 | -0.01 | $6,756 | -$952,343 |
| 2024 Q3 | -0.00 | $4,932 | $107,363 |